COVID-19 Publications

The severity of COVID-19 in children on immunosuppressive medication

Tags: , , , , , , | May 5th, 2020

The number of people with coronavirus disease 2019 (COVID-19) during this ongoing pandemic is rising rapidly. It is already clear that children have considerably better outcomes than adults (particularly older adults ≥70 years), with a mortality of less than 1%. In the adult population, those with pulmonary or cardiac comorbidities have worse outcomes than those without these comorbidities. We are currently managing an ongoing survey that includes children aged 0–19 yearsmwith kidney disease on immunosuppressive medication who are diagnosed with COVID-19. The study was initiated by the European Rare Kidney Disease Reference Network and is supported by the European, Asian, and international paediatric nephrology societies. The members of these societies and the members of the listserv, Pedneph, were asked at regular intervals to include any child in their care fulfilling these criteria. The information was collected in a totally anonymised manner.

Read the full article here.


We would like to update you on our recent activities